Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Axsome Therapeutics Inc's Business Segments
Axsome Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Product
Total Revenue
$ 218
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product0%
- Royalty and Milestone Revenue1.5%
- Royalty1.3%
- Royalty Revenue Sunosi0.3%
- Milestone Revenue Auvelity0.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 406 | - |
| Royalty and Milestone Revenue | $ 3 | 1.5% |
| Royalty | $ 3 | 1.3% |
2 more segments available
Sign in to unlock the full Axsome Therapeutics Inc dataset.
Revenue by Product & Service Category - FY
- Product99.1%
- Royalty and Milestone Revenue0.9%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 216 | 99.1% |
| Royalty and Milestone Revenue | $ 2 | 0.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product0%
- Royalty and Milestone Revenue1.5%
- Royalty1.3%
- Royalty Revenue Sunosi0.3%
- Milestone Revenue Auvelity0.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 406 | - |
| Royalty and Milestone Revenue | $ 3 | 1.5% |
| Royalty | $ 3 | 1.3% |
2 more segments available
Sign in to unlock the full Axsome Therapeutics Inc dataset.
Description of Axsome Therapeutics Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for Central Nervous System (CNS) disorders, including depression, chronic pain, and other neurological conditions. Established in 2012, Axsome has its headquarters in New York, United States.
The company utilizes its proprietary technology and expertise to create novel treatment approaches that offer a new option for patients suffering from CNS disorders. Axsome's core competencies include drug discovery, preclinical and clinical development, and regulatory affairs. The company leverages its strengths and partnerships in these areas to accelerate the development of its therapeutic candidates.
Axsome's portfolio includes several product candidates that are either in the development or clinical testing stage. Some notable candidates include AXS-05, AXS-07, and AXS-1 AXS-05 is a combination of dextromethorphan and an inhibitor of the monoamine oxidase enzyme. This drug is being evaluated for the treatment of major depressive disorder and treatment-resistant depression. AXS-07 is a combination of an anti-inflammatory drug and a triptan, being developed for the treatment of migraines. AXS-12, on the other hand, is being developed for the treatment of narcolepsy.
Axsome has also been actively engaged in several partnership and licensing agreements to advance its pipeline of products. In 2018, the company signed a global license agreement for AXS-05 with Pfizer, which granted them rights to develop and commercialize this product in markets outside the United States. More recently, in 2021, Axsome signed a licensing agreement with Bausch Health that will allow the latter to manufacture and commercialize AXS-07 for migraines in Canada.
The company has been rapidly growing in the past few years, with its share price increasing considerably in response to positive clinical data and regulatory approvals. Axsome has also received several awards and recognitions for its innovative work, including being named as one of the top biotech companies to work for in 2021 by BioSpace.
In conclusion, Axsome Therapeutics Inc is a leading biopharmaceutical company that focuses on the development of innovative therapies for CNS disorders. The company has an extensive portfolio of product candidates, with several in various stages of development and clinical testing. Axsome has been recognized for its innovative work in the field of CNS disorders and has also been actively engaged in strategic partnerships to boost its progress. As the company's pipeline progresses, it has the potential to make a significant impact on the treatment of CNS disorders, particularly in areas where current treatment options are inadequate.
The company utilizes its proprietary technology and expertise to create novel treatment approaches that offer a new option for patients suffering from CNS disorders. Axsome's core competencies include drug discovery, preclinical and clinical development, and regulatory affairs. The company leverages its strengths and partnerships in these areas to accelerate the development of its therapeutic candidates.
Axsome's portfolio includes several product candidates that are either in the development or clinical testing stage. Some notable candidates include AXS-05, AXS-07, and AXS-1 AXS-05 is a combination of dextromethorphan and an inhibitor of the monoamine oxidase enzyme. This drug is being evaluated for the treatment of major depressive disorder and treatment-resistant depression. AXS-07 is a combination of an anti-inflammatory drug and a triptan, being developed for the treatment of migraines. AXS-12, on the other hand, is being developed for the treatment of narcolepsy.
Axsome has also been actively engaged in several partnership and licensing agreements to advance its pipeline of products. In 2018, the company signed a global license agreement for AXS-05 with Pfizer, which granted them rights to develop and commercialize this product in markets outside the United States. More recently, in 2021, Axsome signed a licensing agreement with Bausch Health that will allow the latter to manufacture and commercialize AXS-07 for migraines in Canada.
The company has been rapidly growing in the past few years, with its share price increasing considerably in response to positive clinical data and regulatory approvals. Axsome has also received several awards and recognitions for its innovative work, including being named as one of the top biotech companies to work for in 2021 by BioSpace.
In conclusion, Axsome Therapeutics Inc is a leading biopharmaceutical company that focuses on the development of innovative therapies for CNS disorders. The company has an extensive portfolio of product candidates, with several in various stages of development and clinical testing. Axsome has been recognized for its innovative work in the field of CNS disorders and has also been actively engaged in strategic partnerships to boost its progress. As the company's pipeline progresses, it has the potential to make a significant impact on the treatment of CNS disorders, particularly in areas where current treatment options are inadequate.
Axsome Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies aimed at enhancing the quality of life for patients suffering from serious neurological disorders. The company has structured its operations around four primary therapeutic segments, addressing a range of medical conditions through targeted products and services.
Product Portfolio
1. Migraine
Axsome Therapeutics has placed significant emphasis on migraine treatment, recognizing it as a debilitating condition affecting millions of individuals globally. The companys lead product in this segment, AXS-07, is a combination therapy formulated with Rizatriptan, a well-established triptan, and Meloxicam, a non-steroidal anti-inflammatory drug (NSAID). AXS-07 is engineered to deliver rapid and sustained relief from acute migraine attacks, focusing on both headache pain and associated symptoms, such as nausea. The unique formulation is purported to provide a synergistic effect, enhancing the efficacy of migraine relief while potentially reducing the risk of medication overuse.
Depression
In the realm of mental health, Axsome Therapeutics aims to transform treatment for depression. The companys cornerstone product here is AXS-05, an oral tablet that combines Dextromethorphan, a cough suppressant with neuroprotective properties, and Bupropion, an antidepressant that also has stimulant effects. AXS-05 is undergoing late-stage clinical trials with encouraging results in treating Major Depressive Disorder (MDD) and agitation associated with Alzheimer’s Disease. The dual-action mechanism of AXS-05 is believed to target multiple pathways involved in mood regulation, potentially offering a novel approach to treating depression and related cognitive disorders.
Fibromyalgia
Fibromyalgia is a chronic condition characterized by widespread pain and a variety of other symptoms. Axsomes investigational product for this indication, AXS-14, is specifically targeted at alleviating the symptoms of fibromyalgia by modulating serotonin pathways through the targeting of the 5-HT2A receptor. The product is currently in clinical trials, where it has demonstrated a favorable safety profile alongside preliminary efficacy in pain reduction and improvements in quality of life for patients suffering from this complex disorder.
Pain and CNS Disorders
The companys commitment to addressing pain and various central nervous system (CNS) disorders is exemplified by its development pipeline, which includes AXS-12 and AXS-09. AXS-12 is being explored for its utility in treating narcolepsy and its associated symptom of cataplexy, offering potential benefits in managing excessive daytime sleepiness and sudden muscle weakness. Meanwhile, AXS-09 is under investigation for the treatment of acute pain, focusing on both origin and symptom management.
Services
Apart from its robust product portfolio, Axsome Therapeutics provides a suite of services designed to facilitate the successful development of its therapies:
1. Clinical Trial Management Services
Axsome has assembled a proficient team adept in managing the intricate dynamics of clinical trials. This encompasses site selection, patient recruitment, and retention strategies, ensuring that trials are executed efficiently and effectively.
Regulatory Affairs and Compliance
The regulatory team at Axsome Therapeutics plays a pivotal role in ensuring that all clinical programs adhere to stringent regulatory standards and guidelines set by the FDA and other global regulatory bodies. This function is crucial in maintaining the integrity and safety of the clinical development process.
Medical Affairs
The medical affairs team offers critical medical insight to support ongoing clinical trials while developing educational and promotional materials to enhance understanding and awareness of the companys products. This team serves as a bridge between scientific research and clinical practice.
Business Development
Axsomes business development team is tasked with forging strategic partnerships and collaborations with other entities, including pharmaceutical companies and academic institutions. This function is vital for expanding the companys capabilities and aligning with partners that share a commitment to delivering transformative therapies for neurological conditions.
In summary, Axsome Therapeutics Inc. is at the forefront of developing integrated treatment solutions for patients suffering from neurological disorders. With a comprehensive product portfolio targeting migraine, depression, fibromyalgia, and various pain and CNS conditions, combined with a structured approach to clinical and regulatory operations, the company is positioned as a key player in the biopharmaceutical landscape.
Product Portfolio
1. Migraine
Axsome Therapeutics has placed significant emphasis on migraine treatment, recognizing it as a debilitating condition affecting millions of individuals globally. The companys lead product in this segment, AXS-07, is a combination therapy formulated with Rizatriptan, a well-established triptan, and Meloxicam, a non-steroidal anti-inflammatory drug (NSAID). AXS-07 is engineered to deliver rapid and sustained relief from acute migraine attacks, focusing on both headache pain and associated symptoms, such as nausea. The unique formulation is purported to provide a synergistic effect, enhancing the efficacy of migraine relief while potentially reducing the risk of medication overuse.
Depression
In the realm of mental health, Axsome Therapeutics aims to transform treatment for depression. The companys cornerstone product here is AXS-05, an oral tablet that combines Dextromethorphan, a cough suppressant with neuroprotective properties, and Bupropion, an antidepressant that also has stimulant effects. AXS-05 is undergoing late-stage clinical trials with encouraging results in treating Major Depressive Disorder (MDD) and agitation associated with Alzheimer’s Disease. The dual-action mechanism of AXS-05 is believed to target multiple pathways involved in mood regulation, potentially offering a novel approach to treating depression and related cognitive disorders.
Fibromyalgia
Fibromyalgia is a chronic condition characterized by widespread pain and a variety of other symptoms. Axsomes investigational product for this indication, AXS-14, is specifically targeted at alleviating the symptoms of fibromyalgia by modulating serotonin pathways through the targeting of the 5-HT2A receptor. The product is currently in clinical trials, where it has demonstrated a favorable safety profile alongside preliminary efficacy in pain reduction and improvements in quality of life for patients suffering from this complex disorder.
Pain and CNS Disorders
The companys commitment to addressing pain and various central nervous system (CNS) disorders is exemplified by its development pipeline, which includes AXS-12 and AXS-09. AXS-12 is being explored for its utility in treating narcolepsy and its associated symptom of cataplexy, offering potential benefits in managing excessive daytime sleepiness and sudden muscle weakness. Meanwhile, AXS-09 is under investigation for the treatment of acute pain, focusing on both origin and symptom management.
Services
Apart from its robust product portfolio, Axsome Therapeutics provides a suite of services designed to facilitate the successful development of its therapies:
1. Clinical Trial Management Services
Axsome has assembled a proficient team adept in managing the intricate dynamics of clinical trials. This encompasses site selection, patient recruitment, and retention strategies, ensuring that trials are executed efficiently and effectively.
Regulatory Affairs and Compliance
The regulatory team at Axsome Therapeutics plays a pivotal role in ensuring that all clinical programs adhere to stringent regulatory standards and guidelines set by the FDA and other global regulatory bodies. This function is crucial in maintaining the integrity and safety of the clinical development process.
Medical Affairs
The medical affairs team offers critical medical insight to support ongoing clinical trials while developing educational and promotional materials to enhance understanding and awareness of the companys products. This team serves as a bridge between scientific research and clinical practice.
Business Development
Axsomes business development team is tasked with forging strategic partnerships and collaborations with other entities, including pharmaceutical companies and academic institutions. This function is vital for expanding the companys capabilities and aligning with partners that share a commitment to delivering transformative therapies for neurological conditions.
In summary, Axsome Therapeutics Inc. is at the forefront of developing integrated treatment solutions for patients suffering from neurological disorders. With a comprehensive product portfolio targeting migraine, depression, fibromyalgia, and various pain and CNS conditions, combined with a structured approach to clinical and regulatory operations, the company is positioned as a key player in the biopharmaceutical landscape.